Made, A.C.J.Z.v.d.

tmprs patient tmprss 2-erg 2-erg cancer fusion treatment prostate prostate cancer lymph node metastases expression therapy lymph response metastase survival tmprss 2-erg fusion androgen european sample gene fusion – prostate-speci fic antigen prostate cancer patients psa nadir lymph nodes study european organisation tmprss 2 urology nadir androgen-regulated group androgen-regulated tmprss 2-erg research duration result analysis end points boorman –negative verhagen castration node-positive point metastatic eortc trapman treatment modality mechanism 71 patients polymerase chain reaction stage herman nodal tumour luteinising hormone-releasing hormone paraf turp samples pca patients antigen tmprss 2-erg expression difference androgen –ar axis gene fusion –positive lymph node dissection end point 830–835 cancer-specific tissue population antiandrogen table marker rotterdam organisation death primer tumours tomlin interval